Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zydus Lifesciences' US-based wholly-owned subsidiary, Sentynl Therapeutics, has signed a licensing agreement with South Korea's PRG S&T to acquire full rights to an experimental drug called Progerinin (SLC-D011) for treating Hutchinson-Gilford Progeria Syndrome (HGPS), an ultra-rare genetic disorder that causes rapid aging in children. The drug has already been granted Orphan Drug Designation by the US FDA. Progerinin is currently in late-stage Phase 2A clinical trials, with results expected before the end of the first half of 2026. Upon meeting certain milestones, Sentynl will take full ownership of the molecule, making it Sentynl's second therapy aimed at HGPS. Currently, Zokinvy (lonafarnib) is the only approved treatment for the condition globally. In preclinical mouse studies, Progerinin extended average lifespan to 25.2 weeks compared to 16.8 weeks in untreated subjects.
This is a positive pipeline-expansion move for Zydus, strengthening its rare disease portfolio through Sentynl and addressing a clear unmet medical need. Near-term sentiment could improve on positive Phase 2A data, though commercial revenues from an ultra-rare disease drug are likely to remain modest in the near term.